# "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "

> **NCT02530424** · PHASE2 · COMPLETED · sponsor: **Fondazione Michelangelo** · enrollment: 102 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Palbociclib
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT02530424
- **Lead sponsor:** Fondazione Michelangelo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2019-09
- **Final completion:** 2019-11
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2020-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02530424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02530424, ""Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02530424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*